Tocci Darcy, Fogel Maiah, Gupta Vanya, Kim Peter, Latimer Jean, Adlimoghaddam Aida, Robison Lisa S, Albensi Benedict C
Department of Pharmaceutical Sciences, Barry and Judy Silverman College of Pharmacy, Nova Southeastern University, Fort Lauderdale, FL, USA.
Dr. Kiran C. Patel College of Osteopathic Medicine, Nova Southeastern University, Fort Lauderdale, FL, USA.
Alzheimers Res Ther. 2025 Mar 15;17(1):60. doi: 10.1186/s13195-025-01706-w.
Neurodegenerative diseases, such as Alzheimer's disease (AD), pose a formidable global challenge. While therapeutic options are available, their limitations are significant, necessitating the development of innovative treatment approaches. Here, we highlight the importance of repurposing drugs and discuss the future of drug treatments for AD. We review the potential of tyrosine kinase inhibitors (TKI) for mitigating AD pathology and symptoms, as well as neurodegenerative processes more broadly. We focus on nilotinib, a selective BCR-ABL tyrosine kinase inhibitor, which has unique mechanisms of action involving the modulation of cell responses and removal of toxic proteins associated with AD pathogenesis. Encouraging studies have demonstrated its efficacy, calling for further investigation through clinical trials to assess its potential in various neurodegenerative conditions. However, despite these promising preclinical findings, no clinical studies have yet conclusively demonstrated its efficacy in treating AD. Considering the future directions in AD research, personalized medicine approaches hold promise by incorporating patient-specific factors, including sex and gender differences, to tailor nilotinib treatment for improved efficacy and safety profiles.
神经退行性疾病，如阿尔茨海默病（AD），是一项严峻的全球性挑战。尽管有可用的治疗方案，但其局限性很大，因此需要开发创新的治疗方法。在此，我们强调药物重新利用的重要性，并讨论AD药物治疗的未来。我们回顾了酪氨酸激酶抑制剂（TKI）减轻AD病理和症状以及更广泛的神经退行性过程的潜力。我们重点关注尼洛替尼，一种选择性BCR-ABL酪氨酸激酶抑制剂，它具有独特的作用机制，涉及调节细胞反应和清除与AD发病机制相关的有毒蛋白质。令人鼓舞的研究已经证明了它的疗效，呼吁通过临床试验进行进一步研究，以评估其在各种神经退行性疾病中的潜力。然而，尽管有这些有前景的临床前研究结果，但尚无临床研究最终证明其治疗AD的疗效。考虑到AD研究的未来方向，个性化医疗方法通过纳入患者特定因素（包括性别差异）有望为定制尼洛替尼治疗以提高疗效和安全性提供依据。
